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Introduction. Hyperhomocysteinaemia has recently been identified as an important risk factor for atherosclerotic vascular
disease. Screening for hyperhomocysteinaemia has been recommended, however, the incidence of hyperhomocysteinaemia in
vascular patients is not known.
Aims. To determine the incidence of hyperhomocysteinaemia in vascular patients, to determine the relation of
hyperhomocysteinaemia with folate, vitamin B12 levels and lipid profiles in vascular patients. To examine if there is a
relationship between the degree of vascular injury and homocysteine concentration.
Methods. New vascular patients at The Queen Elizabeth Hospital were recruited and divided into peripheral, and
aneurysmal presentations. Patients demographics were recorded, blood samples were taken for fasting lipid profile, and
homocysteine concentration. Samples were also taken for vitamin B12, plasma and red cell folate levels. Sixty age and sex
matched controls were included for comparison.
Results. One hundred and twenty-six patients have been recruited, (95 men and 31 women) with a median age of 68 years
(61–74 years). The incidence of elevated homocysteine, and cholesterol levels was 33, 47 and 24%. The levels of vitamin B12
and folate were normal in all patients. Homocysteine was elevated in 27% of claudicants, 50% of patients with rest pain and
53% of patients with an aortic aneurysm.
Conclusion. There is a high rate of hyperhomocysteinaemia in vascular patients with a higher incidence in patients with rest
pain. There was also a high incidence of elevated homocysteine levels in patients with an abdominal aortic aneurysm. The
rate of growth of these aneurysms is currently under review. Low folate or B12 concentrations is not the cause of raised
homocysteine levels.
Key Words: Homocysteine; Risk factors; Vascular disease.
Introduction
In 1969, McCully made the clinical observation linking
elevated plasma homocysteine concentrations and
vascular disease.1 Subsequent investigations have
confirmed McCully’s hypothesis, though it is only
recently that sufficient evidence has mounted to
suggest that the association is independent and dose
related, it remains to be established whether it is causal
and modifiable.2
Although severe hyperhomocysteinaemia is rare,
mild hyperhomocysteinaemia (.15 mmol/l) occurs in
5–7% of the general population.2,3 Abundant epide-
miologic evidence has demonstrated that the presence
of mild hyperhomocysteinaemia is an independent
risk factor for coronary, cerebral and peripheral
atherosclerosis.4 As a result of this, recommendations
for screening for hyperhomocysteinaemia have been
made although the incidence of the condition in the
‘vascular community’ is unknown.5
Homocysteine is an amino acid intermediate
formed during the metabolism of the essential amino
acid methionine. It is metabolised by one of two
pathways; remethylation back into methionine or
transulphuration to cystathionine which is converted
into cysteine, and ultimately excreted in the urine
(Fig. 1).
Elevations in plasma homocysteine are typically
caused by either genetic defects in the enzymes
involved in homocysteine metabolism or by nutri-
tional deficiencies in vitamin cofactors. The majority of
the genetic defects such as cystathionine (beta)-
synthase deficiency and homozygous deficiency of
methylenetetrahydrofolate reductase are rare and
result in marked hyperhomocysteinaemia.6,7
Nutritional deficiencies in the vitamin cofactors
(folate, vitamin B12 and vitamin B6) required for
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homocysteine metabolism might promote hyperho-
mocysteinaemia. Elevated homocysteine concen-
trations have been observed in patients with
nutritional deficiencies of the essential cofactor vita-
min B12 and the co-substrate folate.
8,9 It has been
suggested that inadequate plasma concentrations of
one or more of these vitamin cofactors contribute in
approximately two thirds of all cases of hyperhomo-
cysteinaemia.10 Vitamin supplementation can normal-
ise high homocysteine concentrations, however, it
remains to be seen whether normalising homocysteine
concentrations will improve cardiovascular morbidity
and mortality.
Homocysteine can also be increased as part of the
acute phase response, diabetes, chronic renal failure,
cancer and hypothyroidism (Table 1).
The aim of this study was to determine the
incidence of hyperhomocysteinaemia and lipoprotein
(a) concentration in the vascular population, to
determine if there is an association between the degree
of vascular injury and the level of homocysteine or
lipoprotein (b) concentration, and to determine if
patients with hyperhomocysteinaemia have
deficiencies in the vitamin cofactors (folate and
vitamin B12).
Patients and Methods
The study was approved by the local hospital ethics
committee.
All new vascular patients attending the Queen
Elizabeth Hospital were recruited. Patients were
classified into aneurysmal, peripheral and cerebrovas-
cular. The peripheral vascular patients were further
subdivided into claudicants and chronic critical
ischaemia.11 Patient’s demographic data were
recorded including age, risk factor history, past
medical history, and drug history.
Sixty age and sex matched control patients without
vascular disease were recruited from orthopaedic and
general surgery outpatient clinics, as increasing age
and the male sex have been associated with mild
hyperhomocysteinaemia.12
Renal impairment commonly causes hyperhomo-
cysteinaemia because of impaired metabolism of
homocysteine by the kidney, the major route by
which homocysteine is cleared from the plasma.
Plasma homocysteine concentrations can be increased
by various drugs and diseases that interfere with
folate, vitamin B6 and B12 metabolism (Table 1).
13
Patients with these conditions or medications were
excluded.
All blood samples were taken after an overnight
fast, the samples placed on ice and plasma separated
within 60 min and frozen at 220 8C prior to assay.14
Total plasma homocysteine was measured using high
performance liquid chromatography without meth-
ionine loading. Methionine loading stresses the homo-
cysteine metabolic pathways and maybe more
sensitive than a fasting sample, however, this method
is inconvenient for clinician and patient and the
reference values for post load results are uncertain.15
Red cell folate, serum folate and vitamin B12 were
measured using the Abbott AxSYMe kit.
Plasma cholesterol was measured using the Roche
cholesterol kit.
Statistical Analysis
The data were recorded on a proforma and transferred
to Microsoft Excel version 7.0. Statistics were per-
formed using the Excel add-in, Astute (University of
Leeds).
As the data were skewed, non-parametric analyses
were employed. The results are expressed as medians
and interquartile ranges. The Mann–Whitney U test of
significance was used to examine the difference
between results in two groups.
Fig. 1. Homocysteine metabolism.





Malignancy (acute lymphoblastic leukaemia, carcinoma of the
breast, ovary and pancreas
Severe psoriasis
Medications and toxins
Folate antagonists; methotrexate, phenytoin, carbamazepine
Vitamin B6 antagonists; theophyline, nicotinic acid, colestipol
Thiazide diuretics
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Results
One hundred and twenty-six patients have been
analysed, of which 95 men and 31 women, with a
median age of 68 years (IQR 61–74 years). The patients
were divided into claudicants (39 patients), chronic
critical limb ischaemia (CCLI) (40 patients, 26 with rest
pain, 14 with tissue loss) and abdominal aortic
aneurysm (AAA) (47 patients). Moderate hyperhomo-
cysteinaemia has been classified as a value
.16 mmol/l,16 therefore any patients with a homo-
cysteine level .16 mmol/l were counted as elevated.
The incidence of the standard vascular risk factors and
the incidence of elevated homocysteine for all patients
and subdivided as patients with claudication, CCLI
and AAA are shown in Table 2. The control patients
had slightly lower risk factors, but not statistically
significant.
The actual values of homocysteine compared to age
matched controls are shown in Table 3. There is a
statistically significant increase in homocysteine in all
groups, with the CCLI patients having the greatest
increase. There was also a significant difference
between patients with CCLI and claudication
ðp , 0:05Þ. There was no significant difference between
those patients with rest pain and those with tissue loss.
Fifty-three percent of the AAA patients had
moderately raised Hcy levels. All these cases were
infra-renal and none were inflammatory in nature.
Patients with hyperhomocysteinaemia had similar
size aneurysms to those with normal homocysteine
levels (3.9 cm (3.5–7.5) vs. 4.2 cm (3.8–10) p . 0:05).
There was no difference in vitamin B12, serum folate
and red cell folate between vascular patients (medians
400 pmol/l, 28, 625 nmol/l, respectively) and the
control group (medians 356 pmol/l, 24, 576 nmol/l,
respectively, p . 0:05).
Discussion
There is a large body of epidemiological evidence that
links increasing homocysteine (Hcy) with increasing
risk of atherothrombotic vascular disease.17 There is
not complete consistency, and a contrary view has
been proposed that hyperhomocysteinaemia may
represent an acute phase reactant that is a marker of
atherogenesis.18 Plasma homocysteine concentrations
are known to increase after tissue damage, which
could explain the increase noted in the patients with
CCLI compared with claudicants, however, there was
no significant difference between patients with rest
pain or tissue loss.
A striking observation in this study was that 53% of
the AAA patients had elevated Hcy concentrations.
Mild hyperhomocysteinaemia occurs in approxi-
mately 5–7% of the general population3 and according
to this study 27–50% of patients with symptomatic
atherosclerotic vascular disease. None of the aneur-
ysm patients had symptoms of claudication to account
for this increase. The day-to-day variation in fasting
Hcy is small (coefficient of variation 7%),19 so could
not account for the raised levels.
Specimens were placed on ice immediately after
venopuncture until the plasma was separated to
prevent a time and temperature dependent release of
homocysteine from blood cells. Homocysteine also
increases with age and is higher in men, however, the
control group (age and sex matched) had a signifi-
cantly lower homocysteine level than the aneurysm
population and an incidence of hyperhomocysteinae-
mia similar to that previously published.3 The ques-
tion then arises, whether Hcy has a role in aneurysm
formation and/or in aneurysm expansion, or again, is
Hcy simply a marker of the condition? The rate of
expansion of small aneurysms and homocysteine
levels is currently under investigation.
There is one other report in the literature,20 showing
a similar result in the incidence of hyperhomocystei-
naemia in aneurysm patients. They also noted that
patients with hyperhomocysteinaemia had larger
aneurysms than those with normal homocysteine
levels which is different to our own findings.
Nutritional deficiencies in the vitamin cofactors
Table 2. Incidence of risk factors in vascular patients and controls.
All vascular patients Claudicants CCLI AAA Controls
N 126 39 40 47 60
Diabetes 43 (34%) 11 (29%) 15 (38%) 11 (23%) 15 (26%)
Smoking 79 (63%) 21 (53%) 27 (68%) 24 (52%) 24 (40%)
Hypertension 78 (62%) 22 (56%) 27 (68%) 22 (47%) 31 (52%)
Cholesterol (reported on treatment) 46 (46%) 16 (40%) 20 (50%) 18 (39%) 22 (37%)
Cholesterol .5.5 mmol/l 39 (31%) 15 (38%) 11 (29%) 14 (29%) 15 (25%)
Homocysteine .16 mmol/l 46 (37%) 10 (27%) 20 (50%) 25 (53%) 4 (7%)
CCLI, chronic critical limb ischaemia.
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(folate, vitamin B12 and vitamin B6) required for
homocysteine metabolism may promote hyperhomo-
cysteinaemia. Markedly elevated homocysteine concen-
trations have been observed in patients with nutritional
deficiencies of the essential cofactor B12 and the co-
substrate folate.21,22 Selhub and colleagues have
suggested that inadequate plasma concentrations of
one or more B vitamins are contributing factors in
approximately two thirds of all cases of hyperhomocys-
teinaemia23 and that vitamin supplementation can
normalise high homocysteine concentrations. This was
not seen in our study as all folate and vitamin levels were
all within normal limits. It remains to be determined
whether normalising homocysteine concentrations will
improve cardiovascular morbidity and mortality or
influence the rate of aneurysm expansion.
Despite the fact that this was a prospective and
controlled study, limitations did exist. The nature of
the control group was restricted to people attending
hospital, although free of symptomatic vascular
disease, it remains a select group.
Another potential criticism of our method is that
methionine loading was not used in the evaluation of
homocysteine metabolism. However, the development
of sensitive assays by use of high performance liquid
chromatography have led to accurate determinations
of total homocysteine levels without the need for
methionine loading.
Although the data demonstrates a high incidence of
homocysteinaemia in vascular patients, not all
patients in the study group had elevated levels.
Finally, while homocysteinaemia can be reduced
with folate, clinical trial data regarding the potential
benefits of homocysteine lowering therapy for the
prevention of vascular disease are not yet available.
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Table 3. Homocysteine in vascular patients compared to age matched controls. Results are expressed as medians and interquartile ranges.
Claudicants CCLI (rest pain) CCLI (tissue loss) AAA Controls
Cholesterol median (IQR) mmol/l 5.1 (4.7–6.0) 4.9 (3.5–5.5) 4.6 (3.8–5.3) 4.8 (4.5–5.1) 4.5 (4.0–5.9)
Homocysteine median (IQR) mmol/l 12.5 (8.1–18.1) 13.7 (8.3–24.6) 14.1 (9.8–21.2) 17.9 (14.8–20.8) 8.5 (7.0–11.8)
CCLI, chronic critical limb ischaemia; AAA, abdominal aortic aneurysm.
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